Navigation Links
Clinical Update - Debio 025 in Hepatitis C
Date:4/28/2009

LAUSANNE, Switzerland, April 28 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the field of oncology, presented results from a phase IIa study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C (HCV) effect. Revealed at the 44th Annual Meeting of the European Association for the Study of the Liver, in Copenhagen, these findings showed potent antiviral activity.

The phase IIa study investigated the efficacy and safety of Debio 025 in combination with Peg interferon alpha 2a (peg-IFNÿ±2a) and ribavirin in previously null-responder genotype 1 HCV patients. Results demonstrated that Debio 025 at doses of 400 mg (with initial loading) and 800 mg daily for 29 days shows a statistically significant reduction of HCV RNA of respectively -1.96 log (-98.9%) and -2.38 log (-99.5%) when co-administered with Peg-IFN alpha-2a and ribavirin in previous null responders.

"These results in patients who are highly unlikely to respond to re-treatment with an interferon-based regimen, are very important to us, as they confirm that Debio 025 is a potent anti-HCV agent," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "We are making it our mission to find a cure for this widely spread and life threatening disease and these findings bring us one step closer to our goal."

About the phase IIa triple therapy study

Debiopharm investigated different dosing regimens of Debio 025 in combination with peg-IFNÿ±2a at 180 micrograms/week and ribavirin at 1000/1200 mg/day in genotype 1 chronic HCV patients that were previously null responders (< 2 log10 HCV-RNA reduction after 12 weeks with peg-IFN(alpha) 2a and ribavirin). Fifty patients were randomised in an open phase IIa study to receive one of five treatment regimens for 29 days. Afterw
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
4. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
5. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
6. Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
7. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
8. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
9. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
10. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
11. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
(Date:7/30/2015)... 30, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese medicine ... updates regarding the notice it received on May 21, ... that the Company was below certain of the Exchange,s ... and 1101 of the NYSE MKT Company Guide, due ...
(Date:7/30/2015)... LAKE, N.J. , July 30, 2015 ... simultaneously in the United States , ... the FDA, EMA and MHLW, respectively) for eribulin, for ... (STS) who have received prior chemotherapy for advanced or ... based on data from a pivotal global Phase 3 ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... 27, 2011 Water Street Healthcare Partners , ... care, announced today that it has acquired MarketLab, ... firm,s fourth in the specialty healthcare distribution sector.  The ... companies specializing in distribution, life sciences, medical devices and ...
... 2011 Pacira Pharmaceuticals, Inc ., (Nasdaq: ... announced that it has been included in the Russell ... set of U.S. and global equity indexes on June ... measures the performance of the 3,000 largest U.S. companies ...
Cached Medicine Technology:Water Street Healthcare Partners Acquires MarketLab, Inc. 2Water Street Healthcare Partners Acquires MarketLab, Inc. 3Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 2Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 3
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. ... General Hospital Emergency Room – Gilbert, opening in August. The new facility is ... in the West Valley. , “Dr. Baldwin is an excellent leader and will ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... leading provider of medical information, risk management and investigative services, has introduced ... direction toward focused, expert information solutions that improve business outcomes for its ...
(Date:8/2/2015)... ... 03, 2015 , ... A new Phase I research study is looking at ... led by Kenneth G. Lucas, M.D. , chief of the division of pediatric ... at Kosair Children’s Hospital and in the UofL Department of Pediatrics ...
(Date:8/1/2015)... ... ... Back packs can be dangerous? Whaaat?! , Not the danger that guns ... a kid's spine. With school starting again, most kids will be asking for new ... aware of how to help them prevent injuries by understanding backpack safety. , "Carrying ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Tina Wilcoxson, owner ... , Wilcoxson was given that honor by the National Retail Federation, the largest retail ... Wilcoxson was one of three Maine business owners to be named as such. According ...
Breaking Medicine News(10 mins):Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2
... is an essential element of care for children requiring ... combining ketamine and propofol, two common medications used in ... it was unclear whether this practice was superior to ... Research led by Drs. Amit Shah, Gregory Mosdossy ...
... prostate cancer should be especially diligent about having routine ... at the University at Buffalo indicate. , Their findings ... more abnormal colon polyps, known as adenomas, and advanced ... of the research were presented Oct. 19 at a ...
... October 18, 2010 Neuralstem, Inc. (NYSE Amex: ... human clinical trial of the company,s spinal cord stem ... or Lou Gehrig,s disease) at Emory University in Atlanta, ... data from the first six non-ambulatory patients, the trial,s ...
... HealthDay Reporter , MONDAY, Oct. 18 (HealthDay ... victim to stunning medical mistakes, ranging from an operation ... for another patient, a new study finds. To ... Joint Commission in 2004 introduced a universal protocol for ...
... Mozes HealthDay Reporter , MONDAY, Oct. 18 (HealthDay ... may raise the risk for heart attack and stroke, researchers ... short-term, the study team noted. "I don,t want to ... cardiovascular risk in the period just after dental work was ...
... likely to buy unhealthy foods when they pay using ... in the Journal of Consumer Research . ... authors Manoj Thomas (Cornell University), Kalpesh Kaushik Desai (State ... University of New York, Buffalo). "First, there is a ...
Cached Medicine News:Health News:Study reveals superior sedation method for children 2Health News:Prostate cancer patients are at increased risk of precancerous colon polyps 2Health News:Neuralstem updates ALS clinical trial progress 2Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 2Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 3Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 4Health News:Invasive Dentistry May Raise Short-Term Heart, Stroke Risk 2Health News:Invasive Dentistry May Raise Short-Term Heart, Stroke Risk 3Health News:Cash is healthier? Credit and debit increase impulsive food purchases 2
... Isolation Kit (patent pending) is designed for ... / or Newcastle Disease (ND) viral RNA ... samples. This kit id validated by the ... their testing protocol for real-time RT-PCR detection ...
... This revolutionary product will provide ... any type of electroretinogram, visual evoked ... LED ganzfeld will allow you to ... including on-off, double flash, photopic negative ...
... LABOTECH is an automated microplate ... immunoenzymatic microplate techniques. Open architecture ... to many manufacturers' microplate assays ... traditional R.I.A. and I.F.A. methods ...
The Rapidpoint 400/405 instrument is a point-of-care blood gas analyzer that's fast, easy to operate and reliable....
Medicine Products: